You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,450,311

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,450,311 protect, and when does it expire?

Patent 8,450,311 protects MOXEZA and is included in one NDA.

This patent has twenty-three patent family members in fifteen countries.

Summary for Patent: 8,450,311
Title:Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Abstract: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.
Inventor(s): Campins; Inmaculada (Mataro, ES), Jimenez; Nuria (Barcelona, ES), Vidal; Roman (Vallromanes, ES), Carreras; Nuria (Caldes de Montbui, ES), Martinez; Carmen (Llica de Vall, ES), Galan; Francisco Javier (Teia, ES)
Assignee: Novartis AG (Basel, CH)
Application Number:12/474,307
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 8,450,311

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 AT2 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,450,311

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072071   Start Trial
Australia 2009257778   Start Trial
Brazil PI0914971   Start Trial
Canada 2726616   Start Trial
Chile 2009001379   Start Trial
China 102056590   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.